Revolution Medicines, Inc.
NASDAQ:RVMD
40.5 (USD) • At close September 5, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0.742 | 0 | 3.824 | 7.014 | 15.33 | 3.356 | 9.116 | 7.578 | 9.46 | 1.101 | 8.698 | 10.131 | 8.751 | 12.661 | 10.025 | 11.546 | 12.088 | 12.506 | 12.281 | 13.166 | 10.347 |
| Cost of Revenue
| 3.802 | 205.749 | 188.096 | 151.752 | 12.775 | 118.021 | 136.581 | 107.735 | 7.642 | 68.947 | 66.127 | 69.455 | 61.001 | 56.49 | 53.681 | 46.473 | 45.936 | 40.858 | 37.006 | 34.871 | 32.918 | 27.457 | 27.49 | 22.962 | 20.117 | 21.186 | 18.181 |
| Gross Profit
| -3.802 | -205.749 | -188.096 | -151.752 | -12.775 | -118.021 | -135.839 | -107.735 | -3.818 | -61.933 | -50.797 | -66.099 | -51.885 | -48.912 | -44.221 | -45.372 | -37.238 | -30.727 | -28.255 | -22.21 | -22.893 | -15.911 | -15.402 | -10.456 | -7.836 | -8.02 | -7.834 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -183.071 | 0 | -0.998 | -8.83 | -3.314 | -19.696 | -5.692 | -6.454 | -4.675 | -41.21 | -4.281 | -3.033 | -3.229 | -1.754 | -2.284 | -1.378 | -1.274 | -0.836 | -0.638 | -0.609 | -0.757 |
| Reseach & Development Expenses
| 224.134 | 205.749 | 188.096 | 151.752 | 134.932 | 118.021 | 148.481 | 107.735 | 97.981 | 68.947 | 66.127 | 69.455 | 61.001 | 56.49 | 53.681 | 46.473 | 45.936 | 40.858 | 37.006 | 34.871 | 32.918 | 27.457 | 27.49 | 22.962 | 20.117 | 21.186 | 18.181 |
| General & Administrative Expenses
| 40.58 | 35.011 | 28.214 | 23.96 | 21.711 | 22.838 | 18.644 | 15.513 | 14.64 | 13.224 | 10.91 | 10.434 | 10.204 | 9.037 | 8.692 | 7.791 | 7.297 | 6.67 | 5.825 | 5.341 | 5.091 | 5.171 | 4.162 | 3.103 | 2.725 | 2.416 | 3.435 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 40.58 | 35.011 | 28.214 | 23.96 | 21.711 | 22.838 | 18.644 | 15.513 | 14.64 | 13.224 | 10.91 | 10.434 | 10.204 | 9.037 | 8.692 | 7.791 | 7.297 | 6.67 | 5.825 | 5.341 | 5.091 | 5.171 | 4.162 | 3.103 | 2.725 | 2.416 | 3.435 |
| Other Expenses
| 0 | -205.749 | -188.096 | -151.752 | -12.775 | -118.021 | -122.981 | -107.735 | -7.642 | -68.947 | -66.127 | -69.455 | -61.001 | -56.49 | -53.681 | -46.473 | -45.936 | -40.858 | -37.006 | -34.871 | -32.918 | -27.457 | -27.49 | -22.962 | -20.117 | -21.186 | -17.781 |
| Operating Expenses
| 264.714 | 35.011 | 28.214 | 23.96 | 143.868 | 22.838 | 44.144 | 15.513 | 104.979 | 13.224 | 10.91 | 10.434 | 10.204 | 9.037 | 8.692 | 7.791 | 7.297 | 6.67 | 5.825 | 5.341 | 5.091 | 5.171 | 4.162 | 3.103 | 2.725 | 2.416 | 3.835 |
| Operating Income
| -264.714 | -240.76 | -216.31 | -175.712 | -156.643 | -140.859 | -179.983 | -123.248 | -108.797 | -75.157 | -61.707 | -76.533 | -62.089 | -57.949 | -52.913 | -53.163 | -44.535 | -37.397 | -34.08 | -27.551 | -27.984 | -21.082 | -19.564 | -13.559 | -10.561 | -10.436 | -11.669 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -242.565 | 0 | -28.451 | -10.715 | -4.025 | -22.805 | -6.811 | -7.647 | -5.593 | -48.286 | -5.12 | -3.691 | -3.894 | -2.176 | -2.791 | -1.826 | -1.618 | -1.084 | -0.86 | -0.793 | -1.128 |
| Total Other Income Expenses Net
| 16.927 | 27.344 | 20.988 | 19.424 | 23.41 | 24.856 | 18.789 | 10.947 | 10.499 | 7.059 | 5.077 | 2.907 | 0.867 | 0.302 | 0.237 | 0.223 | 0.236 | 0.221 | 0.238 | 0.33 | 0.711 | 0.888 | 0.595 | 0.741 | 0.442 | 0.305 | 0.33 |
| Income Before Tax
| -247.787 | -213.416 | -195.322 | -156.288 | -133.233 | -116.003 | -161.194 | -112.301 | -98.298 | -68.098 | -56.63 | -73.626 | -61.222 | -57.647 | -52.676 | -52.94 | -44.299 | -37.176 | -33.842 | -27.221 | -27.273 | -20.194 | -18.969 | -12.818 | -10.119 | -10.131 | -11.339 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -217.243 | 0 | -25.706 | -9.709 | -3.694 | -21.939 | -6.716 | -7.607 | -5.568 | -48.084 | -5.093 | -3.67 | -3.867 | -2.15 | -2.72 | -1.749 | -1.569 | -1.025 | -0.824 | -0.769 | -1.096 |
| Income Tax Expense
| 0 | 0 | -0.753 | 0 | 0 | 0 | 0.343 | -3.867 | 0 | 0 | -0.123 | -0.297 | 0 | 0 | 0 | 0 | 0 | 0 | 0.362 | 0 | -0.058 | -0.675 | -4.373 | 0 | 0 | 0 | 0 |
| Net Income
| -247.787 | -213.416 | -194.569 | -156.288 | -133.233 | -116.003 | -161.537 | -108.434 | -98.298 | -68.098 | -56.507 | -73.329 | -61.222 | -57.647 | -52.676 | -52.94 | -44.299 | -37.176 | -34.204 | -27.221 | -27.215 | -19.519 | -14.596 | -12.818 | -10.119 | -10.131 | -11.339 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -217.705 | 0 | -25.706 | -9.709 | -3.686 | -21.85 | -6.716 | -7.607 | -5.568 | -48.084 | -5.093 | -3.67 | -3.909 | -2.15 | -2.715 | -1.691 | -1.207 | -1.025 | -0.824 | -0.769 | -1.096 |
| EPS
| -1.134 | -1.13 | -1.13 | -0.94 | -0.81 | -0.7 | -1.14 | -0.99 | -0.92 | -0.62 | -0.63 | -0.87 | -0.81 | -0.77 | -0.71 | -0.72 | -0.6 | -0.53 | -0.52 | -0.42 | -0.46 | -0.67 | -0.4 | -0.35 | -0.28 | -0.28 | -0.31 |
| EPS Diluted
| -1.134 | -1.13 | -1.13 | -0.94 | -0.81 | -0.7 | -1.14 | -0.99 | -0.92 | -0.62 | -0.63 | -0.87 | -0.81 | -0.77 | -0.71 | -0.72 | -0.6 | -0.53 | -0.52 | -0.42 | -0.46 | -0.67 | -0.4 | -0.35 | -0.28 | -0.28 | -0.31 |
| EBITDA
| -260.912 | -237.044 | -212.923 | -172.835 | -153.846 | -138.096 | -129.528 | -121.103 | -107.024 | -72.624 | -54.031 | -74.1 | -59.755 | -55.659 | -50.614 | -51.189 | -42.458 | -35.486 | -32.128 | -25.574 | -25.583 | -18.629 | -18.081 | -11.92 | -9.28 | -9.308 | -10.615 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | -174.566 | 0 | -27.987 | -10.354 | -3.525 | -22.08 | -6.555 | -7.345 | -5.35 | -46.493 | -4.881 | -3.503 | -3.671 | -2.02 | -2.552 | -1.613 | -1.496 | -0.953 | -0.756 | -0.707 | -1.026 |